- Feb 25 | Clinical Research News Contributed Commentary | The use of direct source data capture in clinical research is on the rise, both during clinic visits and remotely by patients. This includes investigator-led and patient self-assessments using laptops or tablet devices, patient diary information using hand-held mobile devices, and wearable sensors that automatically record and transmit various health-related measurements (glucose levels, heart rate, etc.). More
- Feb 20 | Clinical Research News |ORLANDO—A day ahead of the 2020 Summit for Clinical Ops Executives (SCOPE), stakeholders from across the clinical trials enterprise convened for a campfire-style chat on ways to elevate the status of clinical research as a scientific discipline and foster collaboration and pre-competitive knowledge sharing to improve trial conduct. The SCOPE Scientific Symposium (SSS) was led by a half dozen leaders from AbbVie, Pfizer, Biogen, Boston Millennia Partners (BMP), and the Tufts Center for the Study of Drug Development (CSDD), with more than 50 others actively engaged in the dialogue. More
- Feb 19 | Clinical Research News | TrialScout receives the 2020 Participant Engagement Award for its #FindtheFive campaign, a social media campaign that uses TrialScout’s platform to harness the input from the over five million Americans that have participated in some form of clinical research over the past ten years. More
- Feb 18 | Clinical Research News| ORLANDO--IBM Watson Health today unveiled its newest cloud-based technology, IBM Study Advance, at the 11th Annual Summit for Clinical Ops Executives (SCOPE) in Orlando, Florida. The data-driven study design and authoring tool optimizes clinical trial protocol design by merging automated access to real-world patient population data, standardizing protocol template guidance and providing a collaborative workspace designed to facilitate efficiency. More
- Feb 17 | Clinical Research News | Five years ago, phage therapy was a largely unknown approach to treating recalcitrant bacterial infections outside of Eastern Europe. But headline-grabbing stories of bacteriophages bringing people back from the brink of death has catalyzed interest in the century-old practice of using viruses to infect and kill disease-causing bacteria—especially now antimicrobial resistance has limited the usefulness of many antibiotics. More
- Feb 13 | Clinical Research News | To fully appreciate the potential of Adaptive Phage Therapeutics (APT), it’s helpful to review history through the lens of company co-founder and Chief Scientific Officer Carl Merril. For nearly five decades, Carl has been championing the idea of using bacteriophages to treat infectious diseases—an idea for which he has been variably applauded, questioned, ignored, scolded, and, ultimately, vindicated. More
- Feb 12 | Clinical Research News | Perhaps no academic institution has worked longer on the clinical application of phages than Yale University where research efforts are focused on using the pathogen-fighting viruses to re-sensitize bacteria to the antibiotics they’ve grown resistant to. “We’re hoping to drive evolution in the other direction to preserve our antibiotic arsenal for longer,” says Benjamin Chan, Ph.D., associate research scientist in the department of ecology and evolutionary biology, who maintains a large natural-phage library. More
- Feb 11 | Clinical Research News | At least three different types of phage products currently exist, and all of them are being explored as potential therapeutic remedies for people with drug-resistant bacterial infections. These include natural phages that have not been modified at all, as well as genetically engineered phages where one or more of their genes get modified to optimize their killing potential against a pathogen. More
Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc.Feb 25 | This acquisition will spur the development of new drugs to treat complex neurodegenerative conditions, including Alzheimer’s and Parkinson’s disease. More
- Feb 25 | Funding from Biovia, Elsevier, GSK, Novartis, and Roche (and recently BMS), helps build a comprehensive data model and file format for chemical reactions to support Lab of The Future and AI adoption More
Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid TumorsFeb 25 | The release announces a new clinical collaboration with Roche (SIX:RO, ROG), to explore the co-administration of SB 11285, Spring Bank’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced solid tumors. More
- Feb 24 | TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), today announced that Raremark, a patient-data platform focused on rare disease, has partnered with the TriNetX network to bring more clinical trials to its community. More
- Feb 24 | Streck R&D Scientific Manager Dr. Nicholas George will give a presentation on our newest blood collection tube, RNA Complete BCT, at the 27th International Molecular Medicine Tri-Conference in San Francisco. More
- Feb 18 | TrialScope announces the appointment of Craig Lipset and Scott Ballenger to the TrialScope Connect advisory board. TrialScope Connect is an online clinical trial recruitment collective designed address the challenges stakeholders face in accurately matching patients to trials. In advance of the platform’s launch, TrialScope is accepting partner applications from sponsors, healthcare data companies and patient advocacy groups. More
- Feb 18 | Rho Announces Fifth Year as Smile Train Triathlon Title Sponsor The RTP-based Contract Research Organization will continue to show its support at the charity’s 13th annual event in Wake Forest Research Triangle Park, NC ̶ February 17, 2020 ̶ Rho, an RTP-based full-service contract research organization (CRO) focused on bringing new products to market through a complete range of product development services, today announced it is the 2020 Title Sponsor of the 13th annual Smile Train Triathlon, taking place Sunday, June 28 in Wake Forest, North Carolina. This is the fifth year in a row that Rho will be the title sponsor for the event. More
- Feb 18 | International Drug Development Institute (IDDI), a leading therapy-focused Biostatistics and eClinical Services corporation based in Belgium with offices in Boston (MA) and Raleigh (NC) announces that it is hosting a symposium to drive the debate: Are Randomized Clinical Trials Obsolete? Organized with support from the University of Louvain (UCLouvain) and the European Organisation for Research and Treatment of Cancer (EORTC) the symposium will take place at the Auditorium Museum of Fine Arts and Magritte Museum, Brussels, Belgium, on Wednesday, April 22, 2020. More
- Feb 18 | More
Greenphire and Roche Team to Address Critical Clinical Trial Patient Convenience Issues at 11th Annual SCOPE SummitFeb 18 | Greenphire, the global leader in financial software for clinical trials, today announced that it has teamed with top industry sponsor, Roche (SIX: RO, ROG;OTCQX: RHHBY), to address the top hurdles patients face when participating in clinical trials. T More
Learn with DIA! From drug safety and clinical statistics to regulatory affairs and benefit-risk assessment and management across the product lifecycle, DIA brings face-to-face training to you, all year long. Join for a day or two, or for a full week of expert-led education, with group discounts available.
Review and explore upcoming courses in 2020 at www.DIAglobal.org/RSIDM20.
Patient-centric pharma - Advancing the new business model reveals how success can be achieved and provides food for thought on various ways to place patients firmly at the heart of your business and achieve commercially beneficial outcomes.